Trials / Completed
CompletedNCT00662909
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,149 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is intended to test the efficacy, safety and tolerability of two doses of mirabegron against placebo to treat patients with symptoms of overactive bladder
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirabegron | Oral |
| DRUG | Placebo | Oral |
Timeline
- Start date
- 2008-03-28
- Primary completion
- 2009-04-22
- Completion
- 2009-04-22
- First posted
- 2008-04-21
- Last updated
- 2024-11-20
- Results posted
- 2012-10-17
Locations
125 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00662909. Inclusion in this directory is not an endorsement.